B. Jäger

发表

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial

M. Rezai, M. Beckmann, P. Fasching, 2016, Geburtshilfe und Frauenheilkunde.

Circulating tumor cells

K. Griffith, M. Campone, D. Hayes, 2012 .

Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.

U. Jeschke, C. Kuhn, B. Rack, 2012, Translational oncology.

Abstract P4-11-21: Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study

M. Rezai, M. Beckmann, P. Fasching, 2015 .

Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.

P. Fasching, T. Fehm, A. Schneeweiss, 2016, Anticancer research.

P1-07-24: Quantitative and Immunohistochemical Detection of Breast Cancer Cells in Blood Samples.

U. Jeschke, K. Friese, W. Janni, 2011 .

E8. Clinical applications of circulating tumour cells

W. Janni, B. Rack, U. Andergassen, 2012 .

Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting

T. Fehm, N. Stoecklein, H. Neubauer, 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer

U. Jeschke, W. Janni, B. Rack, 2015, Translational oncology.

Differential expression of fructosyllysine-specific receptors on monocytes and macrophages and possible pathophysiological significance

R. Hanschke, S. Krantz, R. Brandt, 1996, Diabetologia.

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

T. Fehm, D. Wallwiener, K. Pantel, 2021, ESMO open.

detect Iv - a multicenter, single arm, phase Ii study evaluating the efficacy of Everolimus in combination with endocrine therapy in patients with Her2-negative, hormone-receptor positive metastatic breast cancer and exclusively Her2-negative circulating tumor cells (ctcs) : Id 450

P. Fasching, T. Fehm, V. Müller, 2014 .

The Renin-Angiotensin System and the Sympathetic Nervous System in Hypertension and Congestive Heart Failure: Implications for Therapeutic Interventions

H. Rupp, B. Jäger, 2001 .

Whole exome analysis to select targeted therapies for patients with metastatic breast or advanced gynecological cancer: a feasibility study

D. Niederacher, N. Krawczyk, T. Fehm, 2022, 64. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V..

520-d Isolation and confinement simulating a flight to Mars reveals heightened immune responses and alterations of leukocyte phenotype

D. Dinges, M. Basner, M. Thiel, 2014, Brain, Behavior, and Immunity.

Moxonidin als Initialtherapie und in Kombination bei der Behandlung der essentiellen Hypertonie: Ergebnisse der Topic-Studie (Trial of Physiotens in Combination)

S. Wonnacott, B. Jäger, Verboom Cn, 2000 .

Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial Of Physiotens In Combination) Study

S. Wonnacott, B. Jäger, Verboom Cn, 1999 .

A Multiplex PCR-Based Next Generation Sequencing-Panel to Identify Mutations for Targeted Therapy in Breast Cancer Circulating Tumor Cells

T. Fehm, H. Neubauer, D. Niederacher, 2020, Applied Sciences.

Studying Side Effects of Tyrosine Kinase Inhibitors in a Juvenile Rat Model with Focus on Skeletal Remodeling

M. Suttorp, J. Tauer, A. Ulmer, 2017 .

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients

K. Pantel, W. Janni, H. Schwarzenbach, 2015, Oncotarget.

Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.

U. Jeschke, K. Friese, W. Janni, 2016, Anticancer research.

Use of Granulocyte‐colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells—Results From the SUCCESS A Trial

M. Beckmann, P. Fasching, T. Fehm, 2018, Clinical breast cancer.

Heparin-induced extracorporal low-density-lipoprotein precipitation (H. E. L. P.) to improve the recovery of hearing in patients with sudden idiopathic hearing loss

K. Schorn, M. Suckfüll, J. Thiery, 2000, European Archives of Oto-Rhino-Laryngology.

Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High‐Risk Early Breast Cancer: Results From the ADEBAR Study

M. Beckmann, P. Fasching, T. Fehm, 2018, Clinical breast cancer.

Breast Cancer: State of the Art and New Findings.

W. Janni, B. Rack, C. Scholz, 2012, Geburtshilfe und Frauenheilkunde.

Presence of disseminated tumor cells in bone marrow correlates with tumor stage and nodal involvement in cervical cancer patients

T. Fehm, W. Janni, F. Taran, 2014, International journal of cancer.

Saving Lives Post-MI: Highly Purified Omega-3 PUFAs for the Prevention of Sudden Death

H. Rupp, B. Jäger, Verboom C-N, 2002 .

Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease.

T. Feyerabend, G. Wiedemann, E. Richter, 2001, International journal of radiation oncology, biology, physics.

301 Survival in Early Breast Cancer Patients is Influenced by Circulating Tumor Cells

M. Beckmann, A. Schneeweiss, H. Tesch, 2012 .

Impact of surgical variables on residual glandular tissue in risk-reducing mastectomies: Results of a retrospective monocentric study from a center of the German consortium for hereditary breast and ovarian cancer.

K. Jannusch, L. Sawicki, N. Bruckmann, 2023, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.